Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
11 hedge funds and large institutions have $131K invested in Evoke Pharma in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0.02% more ownership
Funds ownership: 0.15% → 0.17% (+0.02%)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
19% less capital invested
Capital invested by funds: $161K → $131K (-$30.1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$36.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.2K |
| 3 |
CWP
Concord Wealth Partners
Abingdon,
Virginia
|
+$391 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$20.6K |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$86 |
| 3 |
Morgan Stanley
New York
|
-$19 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $56.7K | – | – | – |
|
2
Geode Capital Management
Boston,
Massachusetts
| $39.7K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $21K | +$36.5K | +932 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $8K | +$10.2K | +261 | +368% |
|
|
5
BlackRock
New York
| $2.8K | -$20.6K | -526 | -81% |
|
6
UBS Group
Zurich,
Switzerland
| $2.1K | – | – | – |
|
|
NA
7
NewEdge Advisors
New Orleans,
Louisiana
| $395 | – | – | – |
|
|
CWP
8
Concord Wealth Partners
Abingdon,
Virginia
| $217 | +$391 | +10 | New |
|
|
LC
9
Lindbrook Capital
Calabasas,
California
| $158 | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $30 | – | – | – |
|
|
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $10 | – | – | – |
|
|
12
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$86 | -3 | Closed |
|
|
13
Morgan Stanley
New York
| – | -$19 | -1 | Closed |
|
EVOK Hedge Fund Activity: Q1 2023 in Review
11 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2023, worth a combined $131K — down 19% from $161K a quarter earlier.
Fund positioning in EVOK was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $36.5K. The largest seller was BlackRock, cutting an estimated $20.6K.
- 11 institutional investors held Evoke Pharma (EVOK) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $131K of Evoke Pharma stock for Q1 2023, down 19% quarter-over-quarter.
- 2 funds opened new Evoke Pharma positions in Q1 2023 and 2 closed out, a net change of 0 holders.
- The largest Evoke Pharma buyer in Q1 2023 was Renaissance Technologies, an estimated $36.5K added.
- The largest Evoke Pharma seller in Q1 2023 was BlackRock, an estimated $20.6K sold.
Based on aggregated 13F filings for Q1 2023.